Related Experiment Video

Updated: Jun 23, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor

Li Yang1, Noboru Yamagata, Rajwardhan Yadav

  • 1Department of Medicine, The Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.

The Journal of Clinical Investigation
|March 6, 2003
PubMed

Insights

The EP2 receptor mediates Prostaglandin E2's immune suppression in cancer. Blocking this receptor in mice reduced tumor growth and enhanced anti-tumor immune responses.

Area of Science:

  • Immunology
  • Cancer Biology
  • Prostaglandin Signaling

Background:

  • Prostaglandin E2 (PGE2), a COX metabolite, influences tumor biology and immune evasion.
  • The EP2 receptor's role in cancer-associated immune deficiency requires further characterization.

Purpose of the Study:

  • To investigate the contribution of the PGE2 EP2 receptor to cancer-associated immune deficiency.
  • To evaluate the impact of EP2 receptor deficiency on tumor growth and anti-tumor immunity.

Main Methods:

  • Utilized EP2(-/-) knockout mice and wild-type littermates challenged with MC26 or Lewis lung carcinoma cell lines.
  • Assessed dendritic cell (DC) differentiation and function in vitro using bone marrow progenitors.
  • Analyzed T cell populations (CD4+, CD8+) and cytotoxic T lymphocyte responses in draining lymph nodes in vivo.

Main Results:

  • EP2(-/-) mice showed significantly reduced tumor growth and increased survival compared to wild-type mice.
  • PGE2 suppressed DC differentiation and function in wild-type mice, an effect absent in EP2(-/-) mice.
  • Tumor-bearing EP2(-/-) mice had increased DC, CD4+, and CD8+ T cells in lymph nodes, with a detectable anti-tumor CTL response.

Conclusions:

  • The EP2 receptor is crucial for PGE2-induced inhibition of DC differentiation and function.
  • EP2 receptor blockade enhances anti-tumor cellular immune responses and reduces tumor progression.

More Related Videos

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...